Genyzme Biosurgery’s Synvisc
This article was originally published in The Gray Sheet
Injectable hyaluronic acid-based viscosupplement to treat osteoarthritis pain in the hip will be evaluated in a clinical trial likely to start later this year. FDA has granted conditional approval for the protocol, Genzyme reports April 16 in Q1 earnings call. Sales of Synvisc to treat knee osteoarthritis pain grew 32% over the year-ago period, contributing to orthopedic revenue of $32.9 mil., up from $24.2 mil. in 2002...
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.